A Phase 3 interventional study of secukinumab low dose and secukinumab high dose in Moderate to Severe Chronic Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing secukinumab in Skin Diseases — none open to participants now, none under way, none of them phase 3. secukinumab · Skin Diseases.
Among the 10 studies testing secukinumab in Skin Diseases, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 3, and was the 9th registered.
497 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.
Browse Skin Diseases studies →None of the 10 studies testing secukinumab in Skin Diseases is open now. The open studies under Skin Diseases, anywhere →
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2018.
This study's enrollment of 84 is above the median of 70 across 375 interventional studies indexed under Skin Diseases.
Median enrollment 156 across the 10 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 2 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
16 studies in Skin Diseases by Novartis: none open now, none under way, none of them phase 3. Of 14 finished, 13 (93%) have results posted.
Among the 16 studies in Skin Diseases by Novartis, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 14th registered.
Novartis’s Skin Diseases studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing secukinumab in Skin Diseases, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 16 in Skin Diseases:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. 84 subjects (most with moderate severity) were enrolled. Subjects were stratified by weight and disease severity.
This was an open-label, parallel group, two-arm, multi-center, trial in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic, plaque psoriasis. The study consists of 3 periods: screening (up to 4 weeks), treatment (Week 208) and post-treatment follow-up (Week 224).
Approximately 80 subjects (at least 60 subjects with moderate psoriasis) were planned to be enrolled in about 40 centers worldwide and targeted to have at least 5 subjects in the \< 25kg body weight, and at least 10 subjects in each of the other two weight groups (25-\< 50 kg and ≥ 50 kg). Adolescents (12-\< 18 years) and children (6-\< 12 years) were included from the beginning of this study, since the DMC had approved already the enrollment of children (6-\< 12 years) in the study CAIN457A2310 (NCT02471144). Subjects received the appropriate dose based on their body weight category.
For the statistical analysis for outcome measures 1 and 2, there was no 'within study' control arm. A historical placebo control was obtained using data from qualifying trials and used as the comparator for the primary and key secondary endpoint analysis. This was in line with the guidance from and discussions with Health Authorities including FDA and EMA (PDCO), which suggested reducing placebo exposure as well as overall clinical trial burden for the pediatric population and accepted an extrapolation approach (EMA 2012). Historical placebo data included in this study were based on clinical appropriateness and alignment of definitions (endpoints, clinical disease population and time point of assessment). Integrated in the analysis were placebo data from Novartis-reported secukinumab adult placebo-controlled studies (CAIN457A2302 (NCT01544595 and NCT01365455), CAIN457A2303 (NCT01544595 and NCT01358578), CAIN457A2308 (NCT01555125) and CAIN457A2309 (NCT01636687)) and pediatric placebo-controlled study CAIN457A2310. In addition, pediatric placebo-controlled study data from the literature on other biologics (e.g. etanercept, ustekinumab) were utilized (Paller et al 2008, Landells et al 2015).
If the subject moved into a higher or lower weight group at two consecutive visits with weight measurements during the maintenance (from Week 12 onwards as assessed at 4 weekly visits or during extension treatment period (as assessed at scheduled site visits), then the subject was dosed according to the new (higher or lower) weight group respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
secukinumab low dose
Drug: secukinumab low dose
secukinumab high dose
Drug: secukinumab high dose
dose depends on the weight group
Also known as: AIN457
dose depends on the weight group
Also known as: AIN457
Number and Percentage of Participants With PASI 75 Response
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 body: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
Time frame: Week 12
Number and Percentage of Participants With IGA Mod 2011 0 or 1 Response
Investigator will assess the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rate the disease from a score of 0 (clear skin) to 4 (severe disease)
Time frame: Week 12
Number and Percentage of Participants With PASI 90 Response
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per the standard procedure. PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
Time frame: Week 12
Secukinumab Concentration in Serum
Mean (Standard Deviation) Secukinumab concentration levels in serum over time.
Time frame: Baleine, Weeks 4, 12, 13, 14, 15, 16, 24, 52, 104, 156, 208
Summary Table of Adverse Events
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Treatment emergent adverse events in this study are events that started after the first dose of study treatment and until 84 days after the last study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 84 days after the last study treatment.
Time frame: Adverse events are reported from the first dose of study-drug until the end of the treatment period (at Week 208) plus 16 weeks additional follow up reporting, for a maximum timeframe of approximately 224 weeks.
A total of 92 subjects were screened of which 84 subjects completed the screening phase and were randomized to the Secukinumab Low dose and High dose groups in a 1:1 ratio.
| Milestone | AIN457 Low Dose | AIN457 High Dose |
|---|---|---|
| Started | 42 | 42 |
| Completed | 31 | 36 |
| Not completed | 11 | 6 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lack of efficacy | 5 | 1 |
| Withdrew: Pregnancy | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Guardian decision | 1 | 0 |
Psoriasis Area and Severity Index (PASI):Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, trunk, upper limbs and lower limbs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, Erythema,Thickening (plaque elevation, induration) \& Scaling(desquamation). Scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section(head: 0.1, upper limbs: 0.2 body: 0.3 lower limbs: 0.4). Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per standard procedure. PASI 75 represents the percentage (or number)of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
| Participants | AIN457 Low Dose | AIN457 High Dose |
|---|---|---|
| Number and Percentage of Participants With PASI 75 Response | 39 | 39 |
Investigator will assess the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rate the disease from a score of 0 (clear skin) to 4 (severe disease)
| Participants | AIN457 Low Dose | AIN457 High Dose |
|---|---|---|
| Number and Percentage of Participants With IGA Mod 2011 0 or 1 Response | 33 | 35 |
Psoriasis Area and Severity Index (PASI) was assessed/calculated as per the standard procedure. PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.
| Participants | AIN457 Low Dose | AIN457 High Dose |
|---|---|---|
| Number and Percentage of Participants With PASI 90 Response | 29 | 32 |
Mean (Standard Deviation) Secukinumab concentration levels in serum over time.
| mcg/mL | AIN457 Low Dose | AIN457 High Dose |
|---|---|---|
| Baseline | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 4 (n=40,40) | 74.2 ± 33.0 | 135 ± 45.3 |
| Week 12 (n=40, 39) | 34.8 ± 10.9 | 69.6 ± 29.2 |
| Week 13 (n=38,33) | 47.1 ± 17.4 | 91.2 ± 34.1 |
| Week 14 (n=40, 39) | 40.9 ± 15.5 | 78.4 ± 29.8 |
| Week 15 (n=38,35) | 34.6 ± 12.4 | 65.7 ± 28.9 |
| Week 16 (n=40,37) | 30.9 ± 11.2 | 55.2 ± 24.9 |
| Week 24 (n=42, 38) | 26.0 ± 10.8 | 48.0 ± 21.4 |
| Week 52 (n=37,38) | 25.0 ± 9.01 | 42.7 ± 17.0 |
| Week 104 (n=39,33) | 21.9 ± 10.8 | 39.3 ± 12.1 |
| Week 156 (n=34,32) | 19.3 ± 8.68 | 35.0 ± 14.1 |
| Week 208 (n=25,28) | 16.7 ± 6.25 | 38.8 ± 17.2 |
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Treatment emergent adverse events in this study are events that started after the first dose of study treatment and until 84 days after the last study treatment, or events present prior to the first dose of treatment which increased in severity based on preferred term within 84 days after the last study treatment.
| Participants | AIN457 Low Dose | AIN457 High Dose |
|---|---|---|
| Subjects with any AE(s) | 33 | 35 |
| Subjects with serious or other significant events - Death | 0 | 0 |
| Subjects with serious or other significant events - Non-fatal SAE(s) | 4 | 2 |
| Subjects with serious or other significant events - Discontinued study treatment due to any AE(s) | 1 | 2 |
Collected over Adverse events are reported from the first dose of study-drug until the end of the treatment period (at Week 208) plus 16 weeks additional follow up reporting, for a maximum timeframe of approximately 224 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 Low Dose | 0/42 (0%) | 4/42 (9.5%) | 30/42 (71.4%) |
| AIN457 High Dose | 0/42 (0%) | 2/42 (4.8%) | 27/42 (64.3%) |
| Event | AIN457 Low Dose | AIN457 High Dose |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 1/42 | 0/42 |
| AppendicitisInfections and infestations | 0/42 | 1/42 |
| COVID-19Infections and infestations | 1/42 | 0/42 |
| Infectious mononucleosisInfections and infestations | 1/42 | 0/42 |
| TonsillitisInfections and infestations | 0/42 | 1/42 |
| Tibia fractureInjury, poisoning and procedural complications | 1/42 | 0/42 |
| Intentional self-injuryPsychiatric disorders | 1/42 | 0/42 |
| Event | AIN457 Low Dose | AIN457 High Dose |
|---|---|---|
| NasopharyngitisInfections and infestations | 13/42 | 7/42 |
| COVID-19Infections and infestations | 11/42 | 9/42 |
| Viral upper respiratory tract infectionInfections and infestations | 1/42 | 7/42 |
| AcneSkin and subcutaneous tissue disorders | 7/42 | 2/42 |
| PyrexiaGeneral disorders | 6/42 | 1/42 |
| Upper respiratory tract infectionInfections and infestations | 0/42 | 6/42 |
| Abdominal painGastrointestinal disorders | 4/42 | 2/42 |
| TonsillitisInfections and infestations | 2/42 | 4/42 |
| EczemaSkin and subcutaneous tissue disorders | 4/42 | 0/42 |
| LeukopeniaBlood and lymphatic system disorders | 3/42 | 1/42 |
| Age, Customized(Participants) | AIN457 Low Dose | AIN457 High Dose | Total |
|---|---|---|---|
| 6 to <12 years | 17 | 16 | 33 |
| 12 to <18 years | 25 | 26 | 51 |
| Sex: Female, Male(Participants) | AIN457 Low Dose | AIN457 High Dose | Total |
|---|---|---|---|
| Female | 20 | 25 | 45 |
| Male | 22 | 17 | 39 |
| Race/Ethnicity, Customized(Participants) | AIN457 Low Dose | AIN457 High Dose | Total |
|---|---|---|---|
| White | 39 | 38 | 77 |
| Black or African American | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| American Indian or Alaska Native | 1 | 4 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Aug 2018 to primary completion in Sep 2019, 12 months.
Results were first posted in Jul 2021, 1 year 10 months after primary completion. A results delay was requested in Jul 2020.
Of 58 industry-sponsored phase 3 interventional studies under Skin Diseases, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 12 months is below that.
Counting every sponsor, half of 60 studies reached it within 19 months; a quarter within 13 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab